Condition evidence map
Weight regain after GLP-1 discontinuation
Research evidence map for the post-discontinuation trajectory: SURMOUNT-4 randomised-withdrawal data, STEP 1 follow-up, and the clinical implications of stopping therapy.
Research context
When incretin therapy is discontinued, trial cohorts typically regain a substantial proportion of the lost weight over the following 12 months. SURMOUNT-4 directly characterised this with a randomised-withdrawal design after a tirzepatide open-label lead-in. STEP 1 follow-up data describe a similar trajectory for semaglutide.
Why this matters metabolically
The biology of central appetite regulation does not become permanently rewired by therapy. The body defends weight, and stopping the pharmacological signal restores the prior trajectory.
FAQs
- Why do people regain weight after stopping GLP-1 therapy?
- The biological appetite-suppression signal of GLP-1 receptor agonism stops when the drug is discontinued. The body's defended weight set-point is unchanged, and food intake typically returns toward baseline.
- Regain trajectory in trial cohorts does not establish individual trajectory.
- Regain is not universal — some patients sustain reduction with lifestyle change, though that is less common.
Related mechanisms
Related peptide profiles
Related trials
Related safety signals
Related conditions
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationAronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)NICE — National Institute for Health and Care Excellence
NICE guidance on treatment pathways for metabolic conditions
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of condition profiles on this site